Intest Res.  2019 Jan;17(1):153-154. 10.5217/ir.2018.00147.

The optimal time to perform an ophthalmic examination of patients with inflammatory bowel disease

• Biancardi
• Troncoso L
• de Moraes Jr HV
• Zaltman C

• KMID: 2438455
• DOI: http://doi.org/10.5217/ir.2018.00147

Abstract

No abstract available.

MeSH Terms

Humans
Inflammatory Bowel Diseases*

Reference

1. Lee HJ, Song HJ, Jeong JH, Kim HU, Boo SJ, Na SY. Ophthalmologic manifestations in patients with inflammatory bowel disease. Intest Res. 2017; 15:380–387.

2. Troncoso LL, Biancardi AL, Moraes HV Jr, Zaltman C. Ophthalmic manifestations in patients with inflammatory bowel disease: a review. World J Gastroenterol. 2017; 23:5836–5848.

3. Biancardi AL, Zaltman C, Troncoso LL, Luiz RR, Moraes HV Jr. The role of clinical-demographic characteristics in ophthalmic manifestations of inflammatory bowel disease. Inflamm Bowel Dis. [published online ahead of print May 11, 2018]. https://doi.org/10.1093/ibd/izy159.

4. Carnahan MC, Goldstein DA. Ocular complications of topical, peri-ocular, and systemic corticosteroids. Curr Opin Ophthalmol. 2000; 11:478–483.

5. Cunningham ET, Zierhut M. TNF inhibitors for uveitis: balancing efficacy and safety. Ocul Immunol Inflamm. 2010; 18:421–423.

6. Cunningham ET Jr, Pasadhika S, Suhler EB, Zierhut M. Drug-induced inflammation in patients on TNF alpha inhibitors. Ocul Immunol Inflamm. 2012; 20:2–5.